Clinical characteristics
| Subject . | Age (years)/gender . | Prior therapy . | Sites of disease . | Marrow BPDCN blasts (course 2) (%) . |
|---|---|---|---|---|
| 1, 1B | 40/M | Cytarabine/daunorubicin/etoposide, ASCT, DLI | Bone marrow, spleen, lymph nodes | 2 (90) |
| 2 | 72/M | Cytarabine/idarubicin, gemcitabine, ASCT × 2 | Skin | 0 |
| 3 | 65/M | Etoposide/doxorubicin/vincristine/prednisone/cyclophosphamide, fludarabine, ASCT | Skin | 1 |
| 4 | 70/M | Decitabine | Skin, bone marrow | 8 |
| 5, 5B | 70/M | None | Skin | 0 (10) |
| 6 | 74/M | Cyclophosphamide/doxorubicin/vincristine/prednisone | Lymph nodes, bone marrow | 1.4 |
| 7 | 70/M | None | Skin | 0.2 |
| 8, 8B | 73/M | None | Skin | 1 (1) |
| 9 | 68/M | Cytarabine/daunorubicin, cytarabine | Skin | 1 |
| 10 | 77/M | None | Skin | 2 |
| 11 | 67/M | Daunorubicin/cytarabine, ASCT, fludarabine, cyclosphosphamide/etoposide/doxorubicin | Bone marrow | 90 |
| Subject . | Age (years)/gender . | Prior therapy . | Sites of disease . | Marrow BPDCN blasts (course 2) (%) . |
|---|---|---|---|---|
| 1, 1B | 40/M | Cytarabine/daunorubicin/etoposide, ASCT, DLI | Bone marrow, spleen, lymph nodes | 2 (90) |
| 2 | 72/M | Cytarabine/idarubicin, gemcitabine, ASCT × 2 | Skin | 0 |
| 3 | 65/M | Etoposide/doxorubicin/vincristine/prednisone/cyclophosphamide, fludarabine, ASCT | Skin | 1 |
| 4 | 70/M | Decitabine | Skin, bone marrow | 8 |
| 5, 5B | 70/M | None | Skin | 0 (10) |
| 6 | 74/M | Cyclophosphamide/doxorubicin/vincristine/prednisone | Lymph nodes, bone marrow | 1.4 |
| 7 | 70/M | None | Skin | 0.2 |
| 8, 8B | 73/M | None | Skin | 1 (1) |
| 9 | 68/M | Cytarabine/daunorubicin, cytarabine | Skin | 1 |
| 10 | 77/M | None | Skin | 2 |
| 11 | 67/M | Daunorubicin/cytarabine, ASCT, fludarabine, cyclosphosphamide/etoposide/doxorubicin | Bone marrow | 90 |
B, second course administered following disease recurrence; DLI, donor lymphocyte infusion; M, male.